Sex and Gender Perspectives in Heart Failure and Regenerative Cardiology

Heart failure affects men and women differently — in pathophysiology, clinical presentation, treatment response, and long-term outcomes — yet sex and gender remain systematically underrepresented in cardiovascular clinical trials and translational research. This gap has real consequences: diagnostic criteria, risk stratification tools, and therapeutic protocols have largely been developed from male-dominated datasets, leaving women and gender-diverse patients underserved.At the same time, the landscape of cardiac care is shifting. Regenerative therapies, biologics, and precision medicine approaches are opening new avenues for cardiac repair — but their sex-specific efficacy and safety profiles remain poorly understood. Hormonal, molecular, and structural differences between male and female hearts influence how disease develops and how these therapies perform, yet few studies have been designed to capture this.This Research Topic brings together clinical, epidemiological, and mechanistic contributions to address these gaps. We particularly encourage submissions from low- and middle-income countries, where sex-disaggregated cardiovascular data remain scarce and the burden of heart failure is growing — including registry-based and cohort studies from sub-Saharan Africa and other underrepresented regions.Subtopics-Sex-specific pathophysiology in cardiomyopathy and heart failure-Hormonal, molecular, and structural determinants of cardiac remodeling; sex differences in disease onset, progression, and phenotype; peripartum cardiomyopathy and other female-predominant conditions-Clinical profiles and outcomes by sex Registry-based and cohort studies examining sex differences in heart failure presentation, hospitalization, and mortality; one-year and long-term outcome data; geographic and regional perspectives, including sub-Saharan Africa.-Disparities in cardiovascular care How biological sex and gender identity influence access to diagnosis, referral pathways, device therapy, and pharmacological treatment; implicit bias in clinical decision-making; policy implications.-Biologics, stem-cell therapy, and regenerative medicine Sex-disaggregated efficacy and safety data for cell-based therapies, growth factors, and tissue engineering approaches; hormonal modulation of regenerative responses; integrating regenerative strategies into heart failure management.-Precision medicine and personalized approaches Sex- and gender-informed risk stratification; biomarker development; tailoring pharmacotherapy and device selection to individual biological profiles. Topic editors: Okechukwu Samuel Ogah, Julius Chacha Mwita Source: https://www.frontiersin.org/research-topics/82425/sex-and-gender-perspectives-in-heart-failure-and-regenerative-cardiology